What is DotBio?
DotBio is a biopharmaceutical innovator specializing in the creation of advanced domain antibody therapies. Leveraging its proprietary DotBody technology platform, the company engineers multi-functional and intracellular antibody treatments derived from stabilized human VH domains. This cutting-edge approach facilitates the rapid development of bi- and tri-specific antibodies, antibody-drug conjugates, and intracellular antibodies, positioning DotBio as a key partner for biopharmaceutical clients seeking sophisticated therapeutic solutions.
How much funding has DotBio raised?
DotBio has raised a total of $5.6M across 1 funding round:
Other Financing Round
$5.6M
Other Financing Round (2023): $5.6M with participation from Proxima Ventures, AIM-HI Accelerator Fund, and Gaorong Capital
Key Investors in DotBio
Proxima Ventures
Proxima Ventures is an investment firm that operates within the investment banking industry, likely focusing on providing capital and strategic guidance to companies within its portfolio.
AIM-HI Accelerator Fund
AIM-HI Accelerator Fund is a non-profit organization dedicated to advancing breakthrough cancer research by providing essential seed funding to early-stage oncology startups, aiming to bridge the gap between laboratory discoveries and clinical applications.
Gaorong Capital
Gaorong Capital, also known as Banyan Capital, is a venture capital firm that focuses on seed stage and growth stage investments in the TMT sector, backed by successful entrepreneurs and world-class foundations.
What's next for DotBio?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for DotBio. This capital infusion is expected to accelerate the company's research and development initiatives, potentially expanding its therapeutic pipeline and market reach. The strategic nature of the investment suggests a focus on scaling operations, forging key partnerships, and advancing its proprietary DotBody technology towards clinical applications and commercialization.
See full DotBio company page
